Investigating why lung cancer outcomes differ for patients of African ancestry
Official title: Molecular mediators of disparate outcomes experienced by patients of African ancestry with lung cancer
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11023305 · Data updated 2026-11-12
This study is looking at why lung cancer might be harder to treat for patients of African ancestry by examining their tumor samples and genetics, and it hopes to find ways to improve treatments for them while also addressing the lack of representation of African Americans in clinical trials.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | December 4, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $368,288 |
| NIH project number | 1R37CA295609-01 |
| Project ID | NIH-11023305 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals of African ancestry who have been diagnosed with lung cancer.
✕Less likely to help
Patients of non-African ancestry or those without a lung cancer diagnosis may not benefit from this research.
What this research studies
This research focuses on understanding the unique molecular factors that contribute to poorer lung cancer outcomes in patients of African ancestry. By analyzing tumor samples and genomic profiles, the study aims to identify specific genetic alterations that may lead to therapeutic resistance. The research will also explore the underrepresentation of African Americans in clinical trials and how this impacts treatment efficacy. Ultimately, the goal is to uncover insights that could improve treatment strategies for this population.
Why it matters
Potential benefit: If successful, this research could lead to more effective lung cancer treatments tailored for patients of African ancestry.
How similar studies have gone: Previous research has indicated that understanding genetic differences can lead to improved treatment outcomes, suggesting potential success for this approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Mcgrail, Daniel James — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Mcgrail, Daniel James
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.